Zealand Pharma A/S announced that it has entered into definitive collaboration agreements with DEKA Research & Development Corp., to develop a continuous infusion pump to be used in combination with dasiglucagon, an investigational agent currently in phase 3 trials in patients with congenital hyperinsulinism. The agreement covers the technical development of the pump system as well as associated manufacturing and commercialization activities. Under the terms of the agreement, DEKA and Zealand will develop a medical pump system that is suitable for use in combination with dasiglucagon. DEKA and its affiliates will be responsible for pump development and pump manufacturing activities. Zealand will be solely responsible for clinical development around the drug-device combination as well as for distribution and commercialization in all territories.